Please login to the form below

Not currently logged in
Email:
Password:

GSK sells Italian research unit to Aptuit

GSK is to sell its Medicines Research Centre in Verona, Italy to Aptuit Inc who will continue to employ all 500 staff who work at the centre
GlaxoSmithKline (GSK) has finalised a deal to sell its Medicines Research Centre in Verona, Italy to Aptuit Inc. As part of the agreement, around 500 staff currently employed at the centre by GSK will be kept on by Aptuit – providing the company with their scientific knowledge and expertise.

Aptuit will supply GSK with R&D services from the facilities. The acquisition will allow Aptuit to provide integrated development services to its global customers while keeping the existing pool of life science research experts in Italy.

The financial terms of the deal have not been disclosed.

Tim Tyson, chairman and CEO of Aptuit said: "This partnership is an example of the developing new model of outsourced R&D collaborations. Verona staff are recognised industry-wide for their drug development expertise and will be an excellent addition to the Aptuit team."

In February 2010, GSK announced plans to cease discovery research in selected neuroscience areas, including depression and pain, to focus on neurodegenerative and neuroinflammatory diseases like Alzheimer's disease, multiple sclerosis and Parkinson's disease. These plans have a direct impact on the Italian R&D facility.

Aptuit specialises in providing contract development and manufacturing services to the pharmaceutical and biotech sectors. This latest acquisition will bring their global portfolio total to 19 locations.

1st July 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics